What is Context Therapeutics Inc's earnings per share (EPS)?

Context Therapeutics Inc (CNTX) reported diluted earnings per share of $-0.38 for fiscal year 2025. This represents a 17.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Context Therapeutics Inc Financials

CNTX

Source SEC Filings (10-K/10-Q) Updated Mar 23, 2026 Currency USD FYE March

This page shows Context Therapeutics Inc (CNTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Context Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, Context Therapeutics Inc generates $0.73 in operating cash flow (-$26.4M OCF vs -$36.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$39.7M

YoY-32.7%

Context Therapeutics Inc's EBITDA was -$39.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.7% from the prior year.

Net Income

-$36.1M

YoY-35.2%

Context Therapeutics Inc reported -$36.1M in net income in fiscal year 2025. This represents a decrease of 35.2% from the prior year.

EPS (Diluted)

$-0.38

YoY+17.4%

Context Therapeutics Inc earned $-0.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 17.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$26.4M

YoY-81.4%

Context Therapeutics Inc generated -$26.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 81.4% from the prior year.

Cash & Debt

$66.0M

YoY-30.1%

5Y CAGR+196.0%

Context Therapeutics Inc held $66.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

92M

YoY+2.4%

Context Therapeutics Inc had 92M shares outstanding in fiscal year 2025. This represents an increase of 2.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-59.7%

YoY-31.7pp

Context Therapeutics Inc's ROE was -59.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 31.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$31.9M

YoY+40.3%

5Y CAGR+81.0%

Context Therapeutics Inc invested $31.9M in research and development in fiscal year 2025. This represents an increase of 40.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$34K

YoY+364.0%

Context Therapeutics Inc invested $34K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 364.0% from the prior year.

CNTX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$31.9M+40.3%	$22.7M+27.7%	$17.8M+150.8%	$7.1M+86.4%	$3.8M+131.8%	$1.6M
SG&A Expenses	$7.8M+8.6%	$7.2M-0.9%	$7.3M-6.4%	$7.8M+114.4%	$3.6M+290.4%	$931K
Operating Income	-$39.7M-32.7%	-$29.9M-19.3%	-$25.1M-63.0%	-$15.4M-46.1%	-$10.5M-309.2%	-$2.6M
Interest Expense	N/A	N/A	$1.2M+112.7%	$547K+751.9%	$64K-90.3%	$661K
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$36.1M-35.2%	-$26.7M-11.5%	-$24.0M-61.5%	-$14.8M-41.9%	-$10.5M-257.4%	$6.6M
EPS (Diluted)	$-0.38+17.4%	$-0.46	$-1.50-61.3%	$-0.93+74.8%	$-3.69	$-3.96

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$8.7M+11.4%	$7.8M+126.1%	$3.5M	N/A	$16.8M+1115.2%	$1.4M-29.8%	$2.0M	N/A
SG&A Expenses	$1.9M-2.0%	$1.9M-6.7%	$2.1M	N/A	$1.9M+10.1%	$1.7M-7.9%	$1.9M	N/A
Operating Income	-$10.6M-8.7%	-$9.8M-76.5%	-$5.5M	N/A	-$18.7M-505.5%	-$3.1M+19.2%	-$3.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	$1.2M+48.0%	$840K+451.5%	$152K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$9.7M-9.8%	-$8.8M-92.9%	-$4.6M	N/A	-$17.5M-674.4%	-$2.3M+38.5%	-$3.7M	N/A
EPS (Diluted)	$-0.10-11.1%	$-0.09-80.0%	$-0.05	N/A	$-0.22-450.0%	$-0.04	$-0.23	N/A

CNTX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$68.5M-30.2%	$98.1M+510.9%	$16.1M-57.7%	$38.0M-26.0%	$51.3M+10878.2%	$467K
Current Assets	$68.4M-30.2%	$97.9M+510.0%	$16.0M-57.6%	$37.9M-26.1%	$51.3M+17022.7%	$299K
Cash & Equivalents	$66.0M-30.1%	$94.4M+553.5%	$14.4M-59.3%	$35.5M-28.5%	$49.6M+16976.1%	$291K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.0M+180.4%	$2.9M-31.8%	$4.2M+30.7%	$3.2M+5.7%	$3.0M-82.6%	$17.4M
Current Liabilities	$8.0M+191.8%	$2.7M-34.4%	$4.2M+30.7%	$3.2M+5.7%	$3.0M-68.2%	$9.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$60.5M-36.5%	$95.3M+702.5%	$11.9M-65.8%	$34.8M-28.0%	$48.3M+385.3%	-$16.9M
Retained Earnings	-$130.9M-38.1%	-$94.8M-39.3%	-$68.1M-54.4%	-$44.1M-50.7%	-$29.3M-55.6%	-$18.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$79.2M-9.1%	$87.2M-6.3%	$93.0M-5.3%	$98.1M+13.7%	$86.3M-15.9%	$102.7M+829.4%	$11.1M-31.2%	$16.1M
Current Assets	$79.1M-9.1%	$86.9M-6.2%	$92.7M-5.3%	$97.9M+13.7%	$86.1M-16.2%	$102.7M+830.3%	$11.0M-31.2%	$16.0M
Cash & Equivalents	$76.9M-7.9%	$83.5M-6.5%	$89.4M-5.4%	$94.4M+11.4%	$84.8M-16.5%	$101.5M+906.4%	$10.1M-30.2%	$14.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M+31.5%	$4.6M+132.4%	$2.0M-30.7%	$2.9M+15.7%	$2.5M+54.1%	$1.6M-38.5%	$2.6M-37.8%	$4.2M
Current Liabilities	$6.0M+32.5%	$4.6M+139.7%	$1.9M-30.9%	$2.7M+17.9%	$2.3M+45.4%	$1.6M-38.5%	$2.6M-37.8%	$4.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$73.2M-11.4%	$82.5M-9.3%	$91.0M-4.5%	$95.3M+13.6%	$83.9M-17.1%	$101.1M+1097.5%	$8.4M-28.9%	$11.9M
Retained Earnings	-$117.9M-9.0%	-$108.2M-8.9%	-$99.4M-4.8%	-$94.8M-3.7%	-$91.4M-23.6%	-$74.0M-3.1%	-$71.7M-5.4%	-$68.1M

CNTX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$26.4M-81.3%	-$14.6M+30.8%	-$21.0M-55.3%	-$13.5M-54.0%	-$8.8M-750.5%	-$1.0M
Capital Expenditures	$34K+364.0%	$7K	$0-100.0%	$37K	$0	N/A
Free Cash Flow	-$26.4M-81.4%	-$14.6M+30.8%	-$21.0M-54.9%	-$13.6M-54.4%	-$8.8M	N/A
Investing Cash Flow	-$2.0M+86.2%	-$14.8M	$0+100.0%	-$537K-114.7%	-$250K	$0
Financing Cash Flow	-$15K-100.0%	$109.3M	$0+100.0%	-$102K-100.2%	$58.4M+4981.9%	$1.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.6M-12.7%	-$5.8M-16.0%	-$5.0M-2.5%	-$4.9M-153.8%	-$1.9M+42.4%	-$3.4M+23.0%	-$4.4M+39.7%	-$7.2M
Capital Expenditures	$0	$0-100.0%	$34K	$0-100.0%	$7K	$0	$0	$0
Free Cash Flow	-$6.6M-12.7%	-$5.8M-15.3%	-$5.1M-3.2%	-$4.9M-152.8%	-$1.9M+42.2%	-$3.4M+23.0%	-$4.4M+39.7%	-$7.2M
Investing Cash Flow	$0	$0+100.0%	-$34K	$0+100.0%	-$14.8M	$0	$0	$0
Financing Cash Flow	$0	$0+100.0%	-$15K-100.1%	$14.5M+32666.3%	-$45K-100.0%	$94.8M	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CNTX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-59.7%-31.7pp	-28.1%+173.8pp	-201.9%-159.2pp	-42.7%-21.0pp	-21.7%	N/A
Return on Assets	-52.7%-25.5pp	-27.2%+122.0pp	-149.2%-110.1pp	-39.1%-18.7pp	-20.4%-1442.1pp	1421.8%
Current Ratio	8.52-27.1	35.62+31.8	3.83-8.0	11.80-5.1	16.90+16.9	0.03
Debt-to-Equity	0.13+0.1	0.03-0.3	0.35+0.3	0.09+0.0	0.06+1.1	-1.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-13.3%-2.6pp	-10.7%-5.7pp	-5.0%	N/A	-20.8%-18.6pp	-2.2%+41.2pp	-43.4%	N/A
Return on Assets	-12.2%-2.1pp	-10.1%-5.2pp	-4.9%	N/A	-20.2%-18.0pp	-2.2%+31.0pp	-33.2%	N/A
Current Ratio	13.10-6.0	19.09-29.7	48.80+13.2	35.62-1.3	36.91-27.1	64.01+59.8	4.23+0.4	3.83
Debt-to-Equity	0.08+0.0	0.06+0.0	0.020.0	0.030.0	0.03+0.0	0.02-0.3	0.31-0.0	0.35
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Adicet Bio Inc ACET

$67.1M

Igm Biosciences, Inc. IGMS

$76.6M

Immix Biopharma Inc IMMX

$473.5M

Connect Biopharma Holdings Ltd CNTB

$167.2M

Sutro Biopharma STRO

$394.0M

Frequently Asked Questions

Is Context Therapeutics Inc profitable?

No, Context Therapeutics Inc (CNTX) reported a net income of -$36.1M in fiscal year 2025.

What is Context Therapeutics Inc's EBITDA?

Context Therapeutics Inc (CNTX) had EBITDA of -$39.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Context Therapeutics Inc's return on equity (ROE)?

Context Therapeutics Inc (CNTX) has a return on equity of -59.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Context Therapeutics Inc's free cash flow?

Context Therapeutics Inc (CNTX) generated -$26.4M in free cash flow during fiscal year 2025. This represents a -81.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Context Therapeutics Inc's operating cash flow?

Context Therapeutics Inc (CNTX) generated -$26.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Context Therapeutics Inc's total assets?

Context Therapeutics Inc (CNTX) had $68.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Context Therapeutics Inc's capital expenditures?

Context Therapeutics Inc (CNTX) invested $34K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Context Therapeutics Inc spend on research and development?

Context Therapeutics Inc (CNTX) invested $31.9M in research and development during fiscal year 2025.

How many shares does Context Therapeutics Inc have outstanding?

Context Therapeutics Inc (CNTX) had 92M shares outstanding as of fiscal year 2025.

What is Context Therapeutics Inc's current ratio?

Context Therapeutics Inc (CNTX) had a current ratio of 8.52 as of fiscal year 2025, which is generally considered healthy.

What is Context Therapeutics Inc's debt-to-equity ratio?

Context Therapeutics Inc (CNTX) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Context Therapeutics Inc's return on assets (ROA)?

Context Therapeutics Inc (CNTX) had a return on assets of -52.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Context Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Context Therapeutics Inc (CNTX) had $66.0M in cash against an annual operating cash burn of $26.4M. This gives an estimated cash runway of approximately 30 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Context Therapeutics Inc's Piotroski F-Score?

Context Therapeutics Inc (CNTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Context Therapeutics Inc's earnings high quality?

Context Therapeutics Inc (CNTX) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.